Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 306

1.

Aortic and Mitral Valve Involvement in Maroteaux-Lamy Syndrome VI: Surgical Implications in the Enzyme Replacement Therapy Era.

Torre S, Scarpelli M, Salviati A, Buffone E, Faggian G, Luciani GB.

Ann Thorac Surg. 2016 Jul;102(1):e23-5. doi: 10.1016/j.athoracsur.2015.11.062.

PMID:
27343522
2.

Genitourinary cancers: molecular determinants for personalized therapies.

Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Raspollini MR, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R.

Urologia. 2016 Jun 23:0. doi: 10.5301/uro.5000187. [Epub ahead of print]

PMID:
27338983
3.

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.

Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F.

Future Oncol. 2016 Jun 17. [Epub ahead of print]

PMID:
27312584
4.

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer.

Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F.

Future Oncol. 2016 Jun 17. [Epub ahead of print]

PMID:
27312426
5.

Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability.

Montironi R, Santoni M, Tartari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M.

Arch Pathol Lab Med. 2016 Jun;140(6):501-2. doi: 10.5858/arpa.2015-0529-LE. No abstract available.

PMID:
27232343
6.

Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3.

Minardi D, Mazzucchelli R, Scarpelli M, Massari F, Ciccarese C, Lopez-Beltran A, Cheng L, Montironi R.

Future Oncol. 2016 Jun;12(12):1431-3. doi: 10.2217/fon-2016-0113. Epub 2016 Mar 30. No abstract available.

PMID:
27189718
7.

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.

Giampieri R, Salvatore L, Del Prete M, Prochilo T, D'Anzeo M, Loretelli C, Loupakis F, Aprile G, Maccaroni E, Andrikou K, Bianconi M, Bittoni A, Faloppi L, Demurtas L, Montironi R, Scarpelli M, Falcone A, Zaniboni A, Scartozzi M, Cascinu S.

Sci Rep. 2016 Apr 27;6:25195. doi: 10.1038/srep25195.

8.

Immunotargeting and personalized therapies in genitourinary cancers.

Mazzucchelli R, Gasparrini S, Galosi AB, Massari F, Ciccarese C, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R.

Future Oncol. 2016 Apr 26. [Epub ahead of print] No abstract available.

PMID:
27113700
9.

Editorial: Emerging Immunotargets in Genitourinary Tumors.

Montironi R, Santoni M, Massari F, Lopez-Beltran A, Cheng L, Berardi R, Scarpelli M.

Curr Drug Targets. 2016;17(7):748-9. No abstract available.

PMID:
27086839
10.

Prostate cancer: from Gleason scoring to prognostic grade grouping.

Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB, Cheng L, Lopez-Beltran A, Briganti A, Montorsi F, Scarpelli M.

Expert Rev Anticancer Ther. 2016 Apr;16(4):433-40. doi: 10.1586/14737140.2016.1160780.

PMID:
27008205
11.

Pathology and Genetics: Tumours of the Urinary System and Male Genital System: Clinical Implications of the 4th Edition of the WHO Classification and Beyond.

Montironi R, Cheng L, Scarpelli M, Lopez-Beltran A.

Eur Urol. 2016 Jul;70(1):120-3. doi: 10.1016/j.eururo.2016.03.011. Epub 2016 Mar 17. No abstract available.

PMID:
26996660
12.

Metabolic phenotype of bladder cancer.

Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R.

Cancer Treat Rev. 2016 Apr;45:46-57. doi: 10.1016/j.ctrv.2016.03.005. Epub 2016 Mar 8. Review.

PMID:
26975021
13.

Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4.

Piva F, Santoni M, Scarpelli M, Briganti A, Lopez-Beltran A, Cheng L, Berardi R, Montorsi F, Montironi R.

Eur Urol. 2016 Mar 3. pii: S0302-2838(16)00239-6. doi: 10.1016/j.eururo.2016.02.049. [Epub ahead of print] No abstract available.

PMID:
26947604
14.

Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.

Piva F, Giulietti M, Santoni M, Occhipinti G, Scarpelli M, Lopez-Beltran A, Cheng L, Principato G, Montironi R.

Mol Diagn Ther. 2016 Apr;20(2):111-7. doi: 10.1007/s40291-016-0192-5. Review.

PMID:
26940073
15.

Emerging Immunotargets and Immunotherapies in Prostate Cancer.

Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M.

Curr Drug Targets. 2016;17(7):777-82.

PMID:
26898309
16.

Emerging Immunotargets in Bladder Cancer.

Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A.

Curr Drug Targets. 2016;17(7):757-70.

PMID:
26844572
17.

Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.

Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L, Bittoni A, Bianconi M, Scarpelli M, Bracci R, Scartozzi M, Cascinu S.

Gastric Cancer. 2016 Jan 21. [Epub ahead of print]

PMID:
26796888
18.

Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Conti A, Santoni M, Burattini L, Scarpelli M, Mazzucchelli R, Galosi AB, Cheng L, Lopez-Beltran A, Briganti A, Montorsi F, Montironi R.

World J Urol. 2015 Dec 22. [Epub ahead of print]

PMID:
26694187
19.

An Overview of Emerging Immunotargets of Genitourinary Tumors.

Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M.

Curr Drug Targets. 2016;17(7):750-6.

PMID:
26648079
20.

Emerging Immunotargets in Metastatic Renal Cell Carcinoma.

Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Holger M.

Curr Drug Targets. 2016;17(7):771-6.

PMID:
26648075
Items per page

Supplemental Content

Loading ...
Write to the Help Desk